Helix BioPharma Corp. (Helix; TSX, FSE: “HBP”) today announced that it has received a milestone payment of USD$125,000 from Lumera Corporation (Lumera; NASDAQ: “LMRA”) under the terms of the license agreement signed between the parties approximately one year ago.
